<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040946</url>
  </required_header>
  <id_info>
    <org_study_id>APACH2</org_study_id>
    <nct_id>NCT04040946</nct_id>
  </id_info>
  <brief_title>Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention</brief_title>
  <acronym>APACH2</acronym>
  <official_title>Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation de l'Avenir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that positron emission tomography with fluorocholline
      (F18-choline PET) will reduce the proportion of unnecessary invasive surgery decisions and
      that the higher cost of positron emission tomography versus MIBI scintigraphy
      (Tc99m-sestaMIBI ) will be offset by lower cost in terms of type. surgery performed wisely
      and complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open, randomized, phase III study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare, between each diagnostic strategy, the proportion of patients for whom the first-line imaging technique guided the surgical procedure wisely</measure>
    <time_frame>Up to 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the diagnostic performance of each strategy by measuring sensitivity and specificity</measure>
    <time_frame>Up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate post-surgical complications by measuring tne number of infections, hematoma</measure>
    <time_frame>Up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Parathyroid Adenoma</condition>
  <condition>Hyperparathyroidism</condition>
  <condition>F18-choline</condition>
  <arm_group>
    <arm_group_label>TEMP-TDM with MIBI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Performing a MIBI scintigraphy, then, in the case of negativity, a F18-choline PET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F18-choline PET</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Realization of F18-choline PET, then, in case of negativity, a MIBI scintigraphy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MIBI scintigraphy</intervention_name>
    <description>Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET</description>
    <arm_group_label>F18-choline PET</arm_group_label>
    <arm_group_label>TEMP-TDM with MIBI</arm_group_label>
    <other_name>F18-choline PET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>F18-choline PET</intervention_name>
    <description>Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy</description>
    <arm_group_label>F18-choline PET</arm_group_label>
    <arm_group_label>TEMP-TDM with MIBI</arm_group_label>
    <other_name>MIBI scintigraphy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient 18 years old

          -  Patient presenting with primary hyperparathyroidism and for whom an excisional surgery
             is planned

          -  For women of childbearing age, negative pregnancy test at Baseline

          -  Biological assessment confirming the diagnosis of primary hyperparathyroidism (high
             serum PTH and calcium concentrations)

          -  Affiliation to a social security scheme

          -  Patient having signed his written consent

        Exclusion Criteria:

          -  Patient deprived of liberty, under tutorship or curatorship

          -  Hypersensitivity to TECNESCAN SESTAMIBI

          -  Any associated medical or psychological condition that could compromise the patient's
             ability to participate in the study

          -  Pregnant or lactating woman

          -  History of parathyroid surgery

          -  Patient with multiple endocrine neoplasia 1 (NEM1)

          -  Known hypersensitivity to fluorocholine or to any of the excipients (sodium chloride,
             water for injections)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>QUAK Elske, MD</last_name>
    <phone>+33 2 31 45 50 02</phone>
    <email>e.quak@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GRELLARD Jean-Michel, Project manager</last_name>
    <phone>+33 (0)2 31 45 50 02</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Béatrice CAVAREC-PEGULLO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Béatrice CAVAREC-PEGULLO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Yves SALAUN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie KEROMNES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gael POTARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie ROUDAUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>QUAK Elske, MD</last_name>
      <phone>+ 33 2 31 45 50 02</phone>
      <email>e.quak@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>QUAK Elske, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>BARDET Stephane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CIAPPUCCINI Renaud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LASNON Charline, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LASNE-CARDON Audrey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BABIN Emmanuel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BASTIT Vianney, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

